Abstract: New compounds, tiacumicins, are produced by a microorganism belonging to the genus Dactylosporangium. The compounds are effective Gram-positive antibiotics.

Abstract: DNA cloning shuttle vectors, including a cosmid shuttle vector, for E. coli and Streptomyces are disclosed. Specifically, disclosed shuttle vectors pAL7002 (NRRL B-18055) and pNJl (NRRL B-18054) contain an E. coli origin of replication, Streptomyces replication functions, and antibiotic resistance markers for both E. coli and Streptomyces. In addition, pNJl contains a cos sequence. Novel 2-norerythromycin antibiotics A, B, C, and D, which were produced in a strain Streptomyces erythreus 12693-240 (NRRL B-18053) transformed by pNJl bearing DNA from Streptomyces antibioticus, are also disclosed. The present invention also provides a method for producing novel antibiotics. This method for antibiotic production is applied to the transformation of a blocked mutant of S. erythreus with genomic DNA from S. antibioticus but may be more broadly applied to genes to antibiotic-producing strains transformed into cells which are blocked in the pathway for production of a different antibiotic.

Abstract: Disclosed herein are fortimicin derivatives represented by the formula: ##STR1## wherein R.sub.z is a monocyclicaryloxycarbonyl amine protecting group, or is loweralkyl, hydroxyloweralkyl, loweracyl, hydroxyloweracyl, or a monocyclicaryloxycarbonyl-protected aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxy-loweralkyl, N,N-diloweralkylaminohydroxyloweralkyl, aminoloweracyl, diaminoloweracyl, N-loweralkylaminoloweracyl, N,N-diloweralkylaminoloweracyl, or aminohydroxyloweracyl; R.sub.1 is hydroxy or loweracyloxy; R.sub.2 is hydrogen, hydroxy or --OR.sub.4, wherein R.sub.4 is tert-butyldimethylsilyl or thiocarbonylimidazoyl; or R.sub.1 and R.sub.2 can be taken together to form ##STR2## wherein R.sub.5 and R.sub.6 are loweralkyl; R.sub.3 is hydroxy or loweracyloxy; and z is a monocyclicaryloxycarbonyl amine protecting group. The compounds are useful as intermediates in the preparation of 3-demethoxyfortimicins.

Abstract: An improved method of producing 2-epi-fortimicin A directly from fortimicin A by protecting the amine functions of fortimicin A, converting the N-protected fortimicin A to an intermediate of the formula: ##STR1## wherein L is a leaving group and Z is an amine-protecting group, reacting the intermediate (I) with a loweralkyl metal halide in N,N-dimethylformamide to form N-protected-2-epi-fortimicin A, and then hydrogenating the N-protected-2-epi-fortimicin A to obtain 2-epi-fortimicin A.

Abstract: 1-Epi-2-deoxyfortimicin B and 4-N-derivatives thereof represented by the formula: ##STR1## wherein: R.sub.1 is hydrogen or loweralkyl and R.sub.2 is selected from the group consisting of loweralkyl, aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl, hydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N,N-diloweralkylaminoloweralkyl, acyl, aminoacyl, diaminoacyl, hydroxyacyl, hydroxy-substituted aminoacyl hydroxy-substituted diaminoacyl, N-loweralkylaminoacyl, N,N-diloweralkylaminoacyl, hydroxy-substituted-N-loweralkylaminoacyl or hydroxysubstituted N,N-diloweralkylaminoacyl with the limitation that R.sub.2 cannot be hydrogen glycyl, formylglycyl or hydantoyl, and the pharmaceutically acceptable salts thereof. The compounds are broad spectrum antibiotics.

Abstract: A method of producing 1-epi-2-deoxyfortimicin A, key intermediates therefor and an improved process for synthesizing the key intermediate 1,2-di-epi-fortimicin A.

Abstract: Derivatives of O-demethylseldomycin factor 5 represented by the following formula are provided: ##STR1## wherein: R is hydrogen or loweralkyl; R.sub.1 and R.sub.2 can be either hydrogen or hydroxy with the limitation that both R.sub.1 and R.sub.2 cannot be hydroxy; R.sub.3 is selected from the group consisting of hydrogen, loweralkyl, aminoloweralkyl, diaminoloweralkyl, hydroxyloweralkyl, N-loweralkylaminoloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, or ##STR2## with the limitation that when R.sub.1 is hydroxy, R.sub.3 cannot be hydrogen when R is hydrogen; and R.sub.4 is selected from the group consisting of loweralkyl, aminoloweralkyl, diaminoloweralkyl, hydroxyloweralkyl, N-loweralkylaminoloweralkyl, aminohydroxyloweralkyl and N-loweralkylaminohydroxyloweralkyl; and the pharmaceutically acceptable salts thereof. The compounds are potent anti-bacterial agents.

Abstract: A new fortimicin, fortimicin AK. The compound is coproduced in the fermentation of Micromonospora olivoasterospora ATCC No. 21819, 31009 or 31010 along with fortimicin A, fortimicin B isofortimicin, fortimicin E and a number of other minor factors. The compound is useful as an intermediate in synthesizing fortimicin AK derivatives which are useful as antibiotics.

Abstract: 4"-O-alkylgentamicins and sagamicins represented by the formula: ##STR1## wherein R.sub.1 is hydrogen or methyl: R.sub.2 is hydrogen or methyl; R.sub.3 is hydrogen or hydroxy; R.sub.4 is hydroxy when R.sub.3 is hydrogen and hydrogen when R.sub.3 is hydroxy; and R.sub.5 is loweralkyl; and the pharmaceutically acceptable salts thereof, intermediates therefor, and compositions and methods employing the potent antibiotics of this invention.

Abstract: A 1-Epi fortimicin represented by the formula ##STR1## wherein: R.sub.1 is hydrogen or loweralkyl; R.sub.2 is hydrogen or hydroxyl, R.sub.3 is selected from the group consisting of hydrogen, loweralkyl, aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl, hydroxyloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N,N-diloweralkylaminohydroxyloweralkyl, acyl, aminoacyl, diaminoacyl, hydroxyacyl, hydroxy-substituted aminoacyl, hydroxy-substituted diaminoacyl, N-loweralkylaminoacyl, N,N-diloweralkylaminoacyl, hydroxy-substituted N-loweralkylaminoacyl or hydroxy-substituted N,N-diloweralkylaminoacyl; R.sub.4 is hydrogen or methyl; and the pharmaceutically acceptable salts thereof.

Abstract: A new seldomycin factor 5 derivative is provided, O-demethylseldomycin factor 5. The compound is represented by the formula: ##STR1## The compound is a potent anti-bacterial agent.

Abstract: 4,N, 2'-N and 4,2'-Di-N-derivatives of fortimicin AM and fortimicin AP are provided by this invention. The compounds are useful as anti-bacterial agents.

Abstract: Derivatives of fortimicin AK are provided by this invention. The derivatives are 4-N, 2'-N- and 4,2'-di-N-derivatives of fortimicin AK which are useful as anti-bacterial agents.

Abstract: 2'-N-substituted fortimicin B and fortimicin B derivatives represented by the formula ##STR1## wherein: R is selected from the group consisting of .beta.-naphthoyl, .gamma.-naphthoyl, .gamma.-naphthyl, (.gamma.-amino-.gamma.-hydroxybutyryl) or 1-(2-amino-4-hydroxybutyl) and R.sub.1 is N-monoloweralkylaminoacyl, N,N-diloweralkylaminoacyl, hydroxy-substituted aminoacyl, an amino acid residue, loweralkyl, aminoloweralkyl, hydroxyloweralkyl, N-loweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N,N-diloweralkylaminohydroxyloweralkyl or hydrogen and the pharmaceutically acceptable salts thereof; pharmaceutical compositions containing the compounds; and methods of making and using the compounds. The compounds are useful as antibiotics.

Abstract: 5-Deoxyfortimicin A, 2,5-dideoxyfortimicin A and the corresponding 4-N-acyl and alkyl fortimicin B derivatives thereof, pharmaceutically acceptable salts thereof, intermediates therefor, and pharmaceutical compositions containing the compounds of this invention. The fortimicin derivatives are represented by the formula: ##STR1## wherein R is selected from the group consisting of acyl, hydroxyacyl, aminoacyl, N-monoloweralkylaminoacyl, N,N-diloweralkylaminoacyl, hydroxyacyl, hydroxy-substituted aminoacyl or an amino acid residue other than glycyl, loweralkyl, aminoloweralkyl, hydroxyloweralkyl, N-monoloweralkylaminoloweralkyl, N-N-diloweralkylaminoloweralkyl or hydroxy-substituted aminoloweralkyl; R.sub.1 is hydrogen or hydroxy; and R.sub.2 is hydrogen or hydroxy with the limitation that either R.sub.1 and R.sub.2 each are hydrogen or when only one of R.sub.1 or R.sub.2 are hydrogen, R.sub.2 is hydrogen and R.sub.1 is hydroxy and R.sub.1 and R.sub.2 both cannot be hydroxy.

Abstract: An improved method for producing the antibiotic 2-deoxyfortimicin A, the method comprising the process of producing said antibiotic directly from fortimicin A in a four step process which results in a 50-60 percent yield of product.

Abstract: Described are novel derivatives of seldomycin factor 5 (XK-88-5) and particularly 3'-Epi-seldomycin factor 5, which exhibit improved activity against gram-positive and gram-negative bacteria resistant to aminoglycoside antibiotics, and a method of preparing them.

Abstract: Described are novel derivatives of seldomycin factor 5 (XK-88-5) and particularly 3'-deoxyseldomycin factor 5, which exhibit improved activity against gram-positive and gram-negative bacteria resistant to aminoglycoside antibiotics, and a method of preparing them.